深圳赛百诺基因公司从诞生之日起,就是超级明星的公司,拥有全球第一个肿瘤基因治疗药物——p53腺病毒注射液(今又生/Gendicine)。但这家以科研和生产人员为主体的企业,总是缺少“做生意”的基因,成立三年后,一度走到破产的边缘,甚至已经发不出工资。这一窘境被徐卫发现。此时徐卫已经做了十多年医药,但一直苦于没有自主知识产权。于是徐卫果断收购了赛百诺 Since its birth, Shenzhen Sembcorn Gene was a superstar company that owns the world’s first cancer gene therapy drug, p53 adenovirus (Gendicine). However, this scientific research and production staff as the mainstay of the enterprise, always lacking in “doing business” gene, three years after its establishment, went to the brink of bankruptcy, and even have been unable to pay wages. This dilemma was discovered by Wei Xu. At this time Xu Wei has done more than 10 years of medicine, but has been suffering from no independent intellectual property rights. So Xu Wei decisively bought Seiborneo